en داروسازي و فارماکولوژِی Pharmacology نامه به سردبیر Letter to the Editor <div style="text-align: justify;"><span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:356.25pt right 6.5in"><span sans-serif="" style="font-family:Aptos,"><span new="" roman="" style="font-family:" times="">Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor for cardiovascular disease. While statins are the cornerstone of LDL-C-lowering therapy, their long-term use may result in dose-dependent adverse effects. Ezetimibe, a Niemann&ndash;Pick C1-Like 1 inhibitor, reduces intestinal cholesterol absorption and complements the reduction of hepatic cholesterol synthesis achieved through statin therapy. Evidence from major trials, including IMPROVE-IT, SHARP, RACING, and EWTOPIA 75, demonstrates that combination therapy achieves greater LDL-C reduction and provides modest improvements in clinical outcomes compared with statin monotherapy, while maintaining a favorable safety profile. The early initiation of combination therapy may permit the use of lower statin doses, thereby reducing adverse effects such as insulin resistance and hepatotoxicity. The co-administration of ezetimibe with statins, when implemented alongside guideline-recommended strategies, represents a rational and patient-centered approach for high-risk individuals. This strategy offers enhanced lipid control and improved safety outcomes relative to statin monotherapy.</span></span></span></span></span></span></div> LDL, Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Hyperlipidemias 404 407 http://jabs.fums.ac.ir/browse.php?a_code=A-10-3487-1&slc_lang=en&sid=1 Narges Yaghoobi نرگس یعقوبی narges.yaghoobi004@gmail.com 2283994004 0009-0001-6823-1847 No Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی فسا، فسا، ایران Mojtaba Farjam مجتبی فرجام farjam.md@gmail.com 2295349117 100319475328460030228 No Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran مرکز تحقیقات بیماری‌های غیرواگیر، دانشگاه علوم پزشکی فسا، فسا، ایران Babak Pezeshki بابک پزشکی babakpezeshki@yahoo.com 100319475328460030229 100319475328460030229 Yes Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran مرکز تحقیقات بیماری‌های غیرواگیر، دانشگاه علوم پزشکی فسا، فسا، ایران